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AbstrACt
Introduction Gynaecological cancers collectively account 
for almost 10% of cancer diagnoses made in Australian 
women. The extent of variation in gynaecological cancer 
survival rates and treatment outcomes across Australia is 
not well documented. The purpose of the clinical quality 
registry described in this paper is to systematically monitor 
and improve quality of care provided to these women, and 
facilitate clinical process improvements to ensure better 
patient outcomes and greater adherence to best practice 
care. The registry infrastructure has been developed in 
conjunction alongside the inaugural ovarian, tubal and 
peritoneal (OTP) module, allowing for concurrent piloting 
of the methodology and one module. Additional tumour 
modules will be developed in time to cover the other 
gynaecological tumour types.
Method and analysis The National Gynae- Oncology 
Registry (NGOR) aims to capture clinical data on all newly 
diagnosed cancers of the uterus, ovary, fallopian tubes, 
peritoneum, cervix, vulva and vagina in Australia with 
a view to using these data to support improved clinical 
care and increased adherence to ‘best practice’. Data are 
sourced from existing clinical databases maintained by 
clinicians and/or hospital gynaecological cancer units. A 
pilot phase incorporating only OTP cancers has recently 
been conducted to assess the feasibility of the registry 
methodology and assess the support of a quality initiative 
of this nature among clinicians and other key stakeholders.
Ethics and dissemination The NGOR has received 
National Mutual Acceptance (NMA) ethics approval from 
Monash Health Human Research Ethics Committee (HREC), 
NMA HREC Reference Number: HREC/17/MonH/198. We 
also have approval from Mercy Health HREC and University 
of Tasmania HREC. Data will be routinely reported back to 
participating sites illustrating their performance against 
measures of agreed best practice. It is through this 
feedback system that the registry will support changes to 
quality of care and improved patient outcomes.
IntroduCtIon
The National Gynae- Oncology Registry 
(NGOR) is a new multi- modular clinical 
quality registry (CQR) which aims to record 
diagnostic, treatment and outcome data 
of patients with newly diagnosed gynaeco-
logical cancers, and to use this information 
to monitor and minimise variation in care, 
improve patient outcomes and identify trends 
and potential gaps in service provision. The 
NGOR was developed by a group of like- 
minded clinicians in collaboration with the 
Cancer Research Program in Monash Univer-
sity’s School of Public Health and Preventive 
Medicine in 2017, and has recently been 
piloted in Victoria, Tasmania and New South 
Wales. It was designed to assess outcomes 
and quality of care provided to women with 
ovarian and related cancers—the first module 
of the NGOR. Other modules of the registry 
will be developed over time, dependent 
on funding, and will be designed around 
anatomical tumour location and similarity in 
management and expected outcomes. The 
NGOR is currently in a transitional phase, 
working to develop these additional modules 
and adjusting the ovarian, tubal and peri-
toneal (OTP) module. The key reason for 
strengths and limitations of this study
 ► We describe the purpose and process of developing 
a national clinical quality registry (CQR) for gynaeco-
logical cancers in Australia, using the ovarian, tubal 
and peritoneal cancer module as an example.
 ► The National Gynae- Oncology Registry was devel-
oped in line with the Australian Operating Principles 
for CQRs (developed in line by the Australian 
Committee of Safety and Quality in Health Care), and 
is managed within the Monash University School of 
Public Health and Preventive Medicine alongside ap-
proximately 30 other clinical registries.
 ► This is a clinician- driven initiative, using a model for 
data collection that should reduce long- term costs 
associated with registry operations through the use 
of previously collected clinical data.
 ► Gynaecological cancers are primarily managed by 
gynaecologic oncologists, who are the key clinical 
group behind this CQR. However, medical oncolo-
gists and other clinical specialities are vital to the 
management of these diseases. Their increased 
engagement and clinical expertise are vital to the 
registry’s future.
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piloting one, rather than all modules, was to allow the 
registry infrastructure to be developed and piloted on a 
smaller scale. Once the registry has matured, additional 
modules can be piloted using—what will then be—an 
established infrastructure.
The registry will in time provide information about 
population- based patterns of care, identify variation in 
treatment patterns and outcomes across Australia, high-
light factors that predict optimal treatment and outcome 
and prompt improved compliance with, best practice- 
based guidelines for the treatment of gynaecological 
cancers. The registry is also expected to improve our 
current understanding of these cancers by monitoring 
trends, providing infrastructure for future research 
studies and determining the clinical effectiveness of treat-
ments in a ‘real- world’ setting.
bACkground
gynaecological cancers in Australia
Malignant tumours of the uterus, ovary, cervix, vulva 
and vagina collectively account for almost 10% of female 
cancer diagnoses made in Australia.7 In 2019, it was esti-
mated that there will be 6454 new cases and 2040 deaths 
attributable to gynaecological cancers.1 There appears 
to be wide variation in the incidence of gynaecolog-
ical cancers across Australia, with women of the lowest 
socioeconomic status (SES) being diagnosed at a more 
frequent rate compared with women of higher SES.2 
Despite limited data, it has been estimated that Aborig-
inal and Torres Strait Islander women are 1.7 times more 
likely to be diagnosed with a gynaecological cancer when 
compared with non- Indigenous women, and are on 
average 10 years younger than their non- Indigenous coun-
terparts (52 vs 62 years of age) when first diagnosed.2 The 
extent of variation in gynaecological cancer survival rates 
and treatment outcomes in hospitals across metropolitan 
and rural areas, and between states and territories is not 
well documented, although it has been reported anec-
dotally. Some variation is believed to be a consequence 
of differences in the prevalence of known risk factors, 
population characteristics, patient choice, availability and 
utilisation of diagnostic services.2 For example, 12% of 
women with epithelial ovarian cancer from an Australia- 
wide population- based study (2002–2005) had a diag-
nostic delay of longer than 6 months. This was more likely 
for women residing in remote Australia and those with 
lower incomes.3 It is also suspected that some variation 
might be explained by differences in quality of care, and 
treatment availability across health services. A population- 
based study of 1192 women diagnosed with ovarian 
cancer in 2005 showed that compared with women from 
relatively socioeconomically advantaged areas, women 
from relatively disadvantaged areas had a 21% higher 
risk of dying during follow- up. A similar difference was 
seen for women living in regional–remote areas versus 
major cities.4 Recent, robust, real- world data to support 
or disprove reports of varied practice across Australia are 
currently not available, with the most recent patterns- of- 
care in ovarian cancer study published in 2002, assessing 
care only within the State of Victoria between 1993 and 
1995.5
Clinical quality registries
CQRs are defined by the Australian Commission of Safety 
and Quality in Healthcare as datasets that systematically 
monitor the effectiveness and appropriateness of health-
care within specified clinical domains (ie, for a partic-
ular disease, condition or device).6 This is accomplished 
through the routine collection, analysis and reporting 
of health- related information from patient’s medical 
records and other administrative data sources. Data are 
subsequently used to identify variation in performance 
in regards to predetermined quality indicators (QIs) that 
measure compliance against best practice, set bench-
marks and inform improvements in healthcare.6 CQRs 
are not intended to completely capture all aspects of care, 
but rather form a solid foundation of data collected from 
the whole population of interest (or as close to 100% 
capture as possible). Thus, ideally a minimal dataset 
is collected, but these data have a definitive purpose, 
informing predetermined measures of adherence to ‘best 
practice’, that is, QIs. A CQR for gynaecological malig-
nancies in Australia would be well placed to identify any 
variation in the management of these cancer types, and 
drive improvements in patient outcomes. Plans for such 
a registry have long been supported by the Australian 
Society of Gynaecologic Oncologists (ASGO).
the inaugural module: otP cancers
Ovarian cancer is the 10th most common cancer in 
Australian women with an estimated 1510 new cases in 
2019, accounting for a quarter of all gynaecological 
cancer diagnoses.7 It is also the most lethal gynaecologic 
malignancy with 1046 Australian women expected to die 
of the disease in 2019.7 Unlike many solid cancers for 
which the 5- year survival rate has collectively increased 
by 20%,8 the 5- year survival rate of women with epithe-
lial ovarian cancer has changed little in recent decades 
with affected women having a 45.7% chance of surviving 
5 years postdiagnosis (2011–2015 data).7 As there are no 
available effective screening tests for this disease,2 the 
symptoms are largely non- specific8 and patients remain 
asymptomatic until the disease is advanced9; it is diffi-
cult to diagnose early when the disease is confined to 
the ovary.2 Though the exact number of cases diagnosed 
at each stage is unknown due to the limited available 
data representing stage at diagnosis in Australia, a large 
proportion of cases (>60%)4 10 are reportedly diagnosed 
at an advanced stage when there is multi- focal metastatic 
disease throughout the peritoneal cavity.2
Given that the most significant prognostic factor for 
ovarian cancer is stage at diagnosis,9 11 with early- stage 
disease considered to be ‘curable’ in 90% of cases,8 the 
research areas of greatest importance for improving 
survival are arguably a means to early detection as well as 
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more timely treatment.8 Until such advances in preven-
tive medicine are made, the greatest chance of improving 
survival for women diagnosed with ovarian cancer is to 
ensure they receive evidence- based high- quality care. 
Hence, the importance for this tumour type is to make up 
the first of the NGOR modules, and the focus of the pilot 
phase. Epithelial fallopian tube and peritoneal cancers 
were also included in the ovarian cancer module because 
of their clinical similarities in treatment and outcomes 
to epithelial ovarian cancer and because many epithelial 
‘ovarian’ cancers originate in the distal fallopian tube.12
key causes of variation in patient outcomes
Patient and disease-related factors
An Australian study published in 2014 investigated survival 
outcomes in Australian women diagnosed with epithe-
lial ovarian cancer and found that poorer survival was 
strongly associated with increasing age and disease stage.4 
It also found strong independent associations between 
poorer patient outcomes and the presence of ascites at 
diagnosis, multiple or severe comorbidities and regional–
remote and relatively disadvantaged areas of residence.4 
The authors’ suggested socioeconomic and geographical 
differences in survival may be attributable in part to diag-
nostic delay and poorer access to treatment.4 The study 
also suggested major variations in unadjusted survival 
rates between states and territories.4 Although variations 
in survival rates did not achieve statistical significance, the 
study was likely underpowered to detect such differences.
BRCA1/2 mutations have been associated with overall 
survival, likely as a result of the high response rate to 
platinum- based chemotherapy; however, the exact nature 
of this effect is yet to be determined.13
Treatment and disease management-related factors
Several studies have demonstrated that better patient 
outcomes including survival are associated with complex 
surgical procedures being performed in specialised hospi-
tals with higher case volumes.14 One study found that a 
hospital volume of ≥21 cases of advanced ovarian cancer 
per year was significantly predictive of improved survival.15 
Prolonged survival has frequently been observed when 
surgery is performed by gynaecological oncologists with 
specialised surgical training.8 16–19 This is likely due to 
achieving optimal or ‘complete’ debulking (cytoreduc-
tion to no macroscopic residual disease).8 14 16 17 19 Some 
authors have reported that gynaecologic oncologists are 
two times more likely to achieve this complete cytoreduc-
tion when compared with other surgeons.19 The extent 
of residual disease is an important prognostic factor 
with significant impact on overall survival, and has been 
recognised as such since 1975.16 17 A meta- analysis by 
Bristow et al showed a survival benefit of 5.5% with every 
10% increase in maximal cytoreduction.17
In addition to the goal of optimal debulking, appro-
priate staging of apparent early stage disease is vital as it 
will help determine whether adjuvant therapy is recom-
mended. One trial found that inadequate staging occurred 
in about 66% of patients, with sampling of lymph nodes 
and diaphragmatic biopsy commonly omitted due to a 
lack of expertise and low case volume of the surgeon.14
MEthods
Project history
A national CQR for gynaecological cancers was first 
proposed in 2014; however, initial attempts to source 
seed funding for this registry were unsuccessful. As the 
reported 5- year survival for women diagnosed with gynae-
cological cancers remains stagnant, the need for real- 
world data on the suspected inconsistencies in quality of 
care became evident. Therefore, a multi- module registry 
was proposed using a novel and more cost- effective meth-
odology to be piloted in gynaecological cancer specialist 
centres across Victoria, Tasmania and New South Wales. 
The aim was to try to align and then collate data from 
existing individual unit databases and pre- existing data-
bases maintained by consultant gynaecologic oncologists.
governance structure
The NGOR is a clinician- driven registry, with a focus on 
initial management and first- line treatment. A Steering 
Committee oversees the registry’s development. Fifteen 
gynaecological oncologists and two medical oncolo-
gists sit on this committee alongside Monash University 
representatives and representatives from registry part-
ners, providing clinical expertise and registry oversight. 
Funding for the pilot phase of the NGOR has been 
supported by Ovarian Cancer Australia, the ASGO and 
the CASS Foundation.
Patient and public involvement
Representatives from Ovarian Cancer Australia, the 
leading national organisation that advocates for those 
affected by ovarian cancer, are members of the Registry 
Steering Committee and were involved in the review, eval-
uation and selection of the OTP cancer QIs. A consumer 
representative also sits on this governing committee.
Participants and opt-out process
Site representatives (clinicians and/or database managers) 
are responsible for assessing eligibility of their patients 
for the registry. The registry uses an opt- out method of 
recruitment whereby participants are informed of their 
enrolment in the registry unless they exercise their right 
to withdraw their participation in the registry. Participants 
can opt- out of the registry at any time either by requesting 
to be removed from the registry entirely (a ‘full’ opt- out) 
or maintaining their medical records but requesting no 
future contact (a ‘partial’ opt- out). The adoption of an 
opt- out method of recruitment is vital for the success 
of the NGOR. It has been demonstrated in other regis-
tries and quality improvement programme that using an 
opt- in model (ie, obtaining written consent in advance 
from potential participants) often results in insufficient 
recruitment of the total eligible population to allow for 
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Figure 1 Participant recruitment and data transfer process in the NGOR. NGOR, National Gynae- Oncology Registry; OTP, 
ovarian, tubal and peritoneal.
meaningful and appropriate assessment of quality of 
care. Whole population recruitment, or as close to this 
as possible, also reduces recruitment bias, by ensuring 
even the sickest and most disadvantaged patients are 
included.20
A waiver of consent for eligible participants who are 
already deceased by the time the registry is informed of 
their diagnosis allows for the collection of these partic-
ipants’ medical data. This is important again to ensure 
whole population capture, and to eliminate bias in 
the recruitment of the potentially more unwell, that 
is patients who may have been diagnosed late and/or 
received care that was not of the same quality as other 
patients with a similar diagnosis. Thus, exclusion of this 
subpopulation because of their inability to consent would 
bias the registry results and limit the ability to fairly risk- 
adjust and benchmark data.
Figure 1 illustrates the NGOR recruitment and data 
collection pathway.
Quality indicators
Data collected in the NGOR will be used to inform the 
QIs developed using current literature, guidelines and 
specialist expertise. Over time, the NGOR will be in a 
position to show whether there is any unwarranted vari-
ation in care across Australia in women with newly diag-
nosed ovarian cancer. Only the QIs for the ovarian cancer 
module have been developed at this stage. The process 
of QI development commenced in 2015 with a review of 
current literature and published guidelines, and gener-
ated a list of 160 possible QIs. These QIs were expansive 
and covered a number of domains including diagnosis, 
staging, pathology, surgery, chemotherapy, radiotherapy 
and other treatment, management and timeliness of care, 
palliation and survival. The Steering Committee reviewed 
this dataset, and developed a shortlist of QIs covering 
key priority areas. In July 2015, members of ASGO were 
surveyed about possible QIs for optimal surgical staging 
and optimal debulking. There were 28 responders 
out of 54 invited (response rate of 52%). Results from 
this survey were considered in subsequent discussions 
about QIs. During two formal meetings of the Steering 
Committee and ongoing discussions, a shortlist of nine 
QIs was created and subsequently revised. These are regu-
larly discussed and modified if appropriate. The current 
set is listed in table 1 and the process of QI development 
is illustrated in figure 2.
trialling a different method for capturing data
This is a non- interventional study primarily using previ-
ously collected clinical data from pre- existing clinical 
databases maintained by consulting gynaecologic oncol-
ogists and gynaecologic oncology units in major public 
hospitals across Australia. The registry pilot aimed to 
demonstrate the feasibility and ease of this predictably 
more cost- effective and sustainable method of registry 
operations given the considerable costs associated with 
manual data collection through medical record review 
by central, trained data collectors who are required to 
interpret clinical notes written for a different purpose. 
This novel method is expected to allow for high- quality, 
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Table 1 Quality indicators for the inaugural NGOR module
Number Quality indicator Data definitions
1 Percentage of patients with apparent stage 
I, II or IIIA OTP cancer who are adequately 
surgically staged.
‘Adequate surgical staging’=where clinically applicable, all of the 
following procedures were performed:
 ► Peritoneal washings (and sent for cytology).
 ► Total abdominal hysterectomy and bilateral salpingo- 
oophorectomy (only in cases where fertility preservation is not a 
priority).
 ► Infra- colic omentectomy or wedge biopsy.
 ► Sampling of pelvic lymph nodes.
 ► Sampling of para- aortic lymph nodes; and.
 ► Appendicectomy (mucinous tumours only).
2 Percentage of patients with newly diagnosed 
OTP cancer who are presented at a multi- 
disciplinary team meeting during which a 
treatment plan was made.
3 Percentage of patients who receive a 
histological or cytological confirmation of 
an OTP cancer diagnosis prior to receiving 
neoadjuvant chemotherapy.
‘Neo- adjuvant’ chemotherapy here indicates any chemotherapy 
given to the patient prior to any planned debulking procedure (even 
when the patient did not subsequently undergo surgery for clinical 
reasons).
4 Percentage of women with newly diagnosed 
OTP cancer who receive first- line 
chemotherapy that is platinum- based.
5 Percentage of patients with advanced OTP 
cancer undergoing primary debulking surgery.
i. have optimal debulking to no macroscopic 
residual cancer, or
ii. have optimal debulking to ≤1 cm 
macroscopic residual cancer
‘Advanced’=stages IIB, IIIB, IIIC and IV (International Federation of 
Gynecology and Obstetrics (FIGO) classification)
‘Primary debulking’=debulking surgery performed after 0 cycles of 
chemotherapy
‘Interval debulking’=debulking surgery performed after 3–4 cycles 
of chemotherapy
6 Percentage of patients with advanced OTP 
cancer who undergo interval debulking surgery:
i. Have optimal debulking to no macroscopic 
residual cancer, or
ii. Have optimal debulking to ≤1 cm 
macroscopic residual cancer.
7 Percentage of major operations for epithelial 
OTP cancer with an adverse event occurring 
within 30 days of surgery.
Intraoperative complications=blood loss of >2 units or any injury 
caused during the surgery, to the bladder, ureter, small or large 
bowel, vascular system or nerve(s).
8 Percentage of major operations for epithelial 
OTP cancer with an adverse event occurring 
within 30 days of surgery.
Where ‘adverse events’ includes:
 ► Unplanned return to 
theatre;
 ► Unplanned admission to 
ICU;
 ► Unplanned admission to 
CCU;
 ► Unplanned readmission to 
hospital;
 ► Death;
 ► Or one of the following:
 ► o Anastomotic leak
 ► o Small bowel obstruction
 ► o Urinary tract injury
 ► o Postoperative haemorrhage
 ► o Infection requiring antibiotics
 ► o Prolonged ileus (≥7 days)
 ► o Peritonitis
 ► o Thromboembolism
 ► o Pneumonia and/or 
pneumothorax
 ► o Lymphocyst
9 Percentage of women with newly diagnosed 
OTP cancer who receive a referral for, or are 
offered, genetic testing.
CCU, critical care unit; ICU, intensive care unit; NGOR, National Gynae- Oncology Registry; OTP, ovarian, tubal and peritoneal.
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Figure 2 Process of QI development for the inaugural NGOR module. ASGO, Australian Society of Gynaecologic Oncology; 
NGOR, National Gynae- Oncology Registry; OTP, ovarian, tubal and peritoneal; QI, quality indicator.
consistent data collection in a more time and cost- effective 
method, avoiding duplication of effort.
A database alignment phase performed in mid-2017 
involved the assessment of the various data items required 
to inform the nine QIs. This found that all the site data-
bases contained sufficient data on the QIs. Following some 
minor adjustments to these existing datasets, the NGOR 
will continue to follow this method of data collection.
Data will be collected from the time of diagnosis until 
the date of death or registry closure, allowing for the 
comparison of variations in outcome and clinical practice 
across individual units, across the private versus public 
sector and regional versus metropolitan centres as well 
as facilitate national and international benchmarking 
against agreed best practice.
The NGOR will collect data on women with gynaecolog-
ical cancers until there is clear and consistent evidence of 
best practice care provision nationwide. Data collection 
has already commenced for one module, and remaining 
modules will commence data collection and participant 
recruitment in mid- to late-2020
All current participating sites and clinicians involved 
already collect patient data for clinical purposes and 
agreed to contribute relevant data items from these 
databases to the NGOR. Together these account for 
the majority of public gynaecologic oncology treatment 
centres in the participating states. Although commencing 
with the recruitment of these specialist centres may intro-
duce bias to the dataset and not accurately represent the 
Australian population being treated for these cancers, it 
has been deemed as the most cost- effective and feasible 
methodology and will not limit the growth of the registry 
over time. Other smaller centres without major gynaeco-
logic oncology units, as well as the units in other as- of- yet 
not participating states will be recruited once registry 
methodology and each module’s QI set has been assessed 
for usefulness and feasibility of collection. The registry 
will gradually work towards the ultimate target of total 
population capture, or as close to this as possible.
Datasets are imported at regular time points into the 
registry, housed in Monash University’s Department of 
Epidemiology and Preventive Medicine, through a secure 
portal, and this process is expected to inform most of the 
registry outputs. In the future, if sites without databases 
wish to contribute to the registry, the methodology will 
need to be adapted and may reflect that of other CQRs, 
or may involve assisting sites to maintain a NGOR stan-
dard site- based database which can sync with the registry. 
Alternatively, sites may choose to enter data directly into 
the registry. In this instance, limited access to the regis-
try’s electronic database will be granted allowing specific 
site personnel access to only that site’s records.
data cleaning, analysis and reporting
Data entered into the registry is cleaned by the registry 
coordinator, and where necessary and appropriate, modi-
fied to adhere to registry data structures. Data will be 
risk- adjusted using additional data items such as comor-
bidity data, participant age, body mass index and stage 
at diagnosis, to ensure that fair comparisons between 
institutions and clinicians can be made. Data will then be 
aggregated and reported against the predetermined QIs. 
No identifying or potentially reidentifiable data will be 
published. Participating sites and clinicians will receive 
regular benchmarked reports once the CQR has reached 
maturity, illustrating how their performance in respect to 
each QI compares with their deidentified counterparts. 
Outliers (defined as indicator performance that is outside 
three SDs from the mean performance of their peers) 
identified in these reports will prompt site- led investiga-
tions into causes for variation, and drive improvements in 
clinical care. This process is illustrated in figure 3.21
An outlier management policy developed by Monash 
University registry experts will guide the Steering 
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Figure 3 The data process in the NGOR. Adapted from 
the Australian Commission on Safety and Quality. Boxes 
shaded in grey represent the actions of the registry, The 
remaining actions are those of the hospital, health service 
and/or individual clinician. NGOR, National Gynae- Oncology 
Registry; QI, quality indicator.
Committee’s actions if, a significant and persistently 
poorly performing outlier is identified, to ensure there 
is a clear framework for verification, investigation and 
resolution of the cause. Sites identified as performing 
poorly against a QI will be provided ample opportunity to 
review their data, and the registry data and methodology 
will be audited to ensure that any publicly reported QI 
performance is a true reflection of care provision and not 
that of data collection error or misinterpretation of data. 
Furthermore, the registry Steering Committee will be 
required to approve requests for data access in the event 
that researchers, internal or otherwise, wish to access 
NGOR data for additional research and publication.
EthICs And dIssEMInAtIon
Data collected for the registry will be routinely reported 
back to participating sites illustrating their performance 
against the various QIs, in addition to annual reports 
that will be publicly available showing registry growth 
and achievements. It will be the generation and distribu-
tion of routine QI reports that the registry will help drive 
improvements to care provision and to the improvement 
of outcomes for Australian women with gynaecological 
cancers.
the future
The registry is currently in a transition phase, with funding 
secured for additional modules to be developed and run 
within the piloted framework, alongside the continuing 
OTP module. The establishment of the NGOR allows 
Australia to quantify variation and improve outcomes for 
patients with gynaecological cancers, and facilitate adher-
ence to best practice care nationally.
Over time, as a greater proportion of the population- 
of- interest are recruited to the registry, the registry 
should increase its potential to identify variation across 
high versus low volume sites, remote versus regional sites 
and draw other comparisons. In recruiting high- volume 
sites first, solid evidence of ‘best practice’ and what is 
achievable realistically with the greatest resources and 
specialist involvement, the registry should provide a solid 
framework against which future lower volume and less- 
established sites can be compared against both in perfor-
mance against QIs as well as fundamental aspects of 
clinical management that may be amenable. By providing 
indisputable evidence of the impact of known barriers to 
best practice care for remote and low- volume centres, the 
registry aims to improve care nationwide.
The NGOR Steering Committee intends to incorpo-
rate the collection of patient- reported outcomes (PROs) 
in the future, to compliment the clinical data on quality 
of care. PROs will provide additional information that 
can only be obtained from patients about quality of care, 
and is invaluable to a CQR such as this. Patient- reported 
outcome measures are not currently used in the registry as 
the best and more appropriate tool, as well as the method 
with which they will be incorporated to the registry, 
and how the data will be used must be determined in a 
substudy. This is planned for the near future, but could 
not be performed before the clinical data requirements 
were finalised.
ConClusIon
Until significant advances in diagnostic technology, and 
the development of more effective therapies for gynae-
cological cancers become available for routine care, opti-
mising survival for women diagnosed with these diseases 
will rely on the delivery of timely, evidence- based care. A 
CQR such as the NGOR is a valuable method for assessing 
the current quality of care provided to these women, 
identifying where variation may exist, and prompting 
service- level change to improve patient outcomes. This 
is of particular importance in ensuring care is equitable, 
and working towards uniform clinical quality that does 
not vary significantly by geographical region or across 
demographic subgroups.
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